Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2007 1
2008 1
2014 1
2019 1
2020 2
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

7 results

Results by year

Filters applied: . Clear all
Page 1
A randomized phase II study of metronomic cyclophosphamide and methotrexate (CM) with or without bevacizumab in patients with advanced breast cancer.
Mayer EL, Tayob N, Ren S, Savoie JJ, Spigel DR, Burris HA 3rd, Ryan PD, Harris LN, Winer EP, Burstein HJ. Mayer EL, et al. Among authors: savoie jj. Breast Cancer Res Treat. 2024 Feb;204(1):123-132. doi: 10.1007/s10549-023-07167-9. Epub 2023 Nov 29. Breast Cancer Res Treat. 2024. PMID: 38019444 Clinical Trial.
Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer.
Garrido-Castro AC, Saura C, Barroso-Sousa R, Guo H, Ciruelos E, Bermejo B, Gavilá J, Serra V, Prat A, Paré L, Céliz P, Villagrasa P, Li Y, Savoie J, Xu Z, Arteaga CL, Krop IE, Solit DB, Mills GB, Cantley LC, Winer EP, Lin NU, Rodon J. Garrido-Castro AC, et al. Among authors: savoie j. Breast Cancer Res. 2020 Nov 2;22(1):120. doi: 10.1186/s13058-020-01354-y. Breast Cancer Res. 2020. PMID: 33138866 Free PMC article. Clinical Trial.
Barriers to Clinical Trial Accrual: Perspectives of Community-Based Providers.
Knelson LP, Cukras AR, Savoie J, Agarwal A, Guo H, Hu J, Fell G, Lederman R, Hughes ME, Winer EP, Lin NU, Tolaney SM. Knelson LP, et al. Among authors: savoie j. Clin Breast Cancer. 2020 Oct;20(5):395-401.e3. doi: 10.1016/j.clbc.2020.05.001. Epub 2020 May 7. Clin Breast Cancer. 2020. PMID: 32605813
The Immune Microenvironment in Hormone Receptor-Positive Breast Cancer Before and After Preoperative Chemotherapy.
Waks AG, Stover DG, Guerriero JL, Dillon D, Barry WT, Gjini E, Hartl C, Lo W, Savoie J, Brock J, Wesolowski R, Li Z, Damicis A, Philips AV, Wu Y, Yang F, Sullivan A, Danaher P, Brauer HA, Osmani W, Lipschitz M, Hoadley KA, Goldberg M, Perou CM, Rodig S, Winer EP, Krop IE, Mittendorf EA, Tolaney SM. Waks AG, et al. Among authors: savoie j. Clin Cancer Res. 2019 Aug 1;25(15):4644-4655. doi: 10.1158/1078-0432.CCR-19-0173. Epub 2019 May 6. Clin Cancer Res. 2019. PMID: 31061067 Free PMC article.
VEGF as a marker for outcome among advanced breast cancer patients receiving anti-VEGF therapy with bevacizumab and vinorelbine chemotherapy.
Burstein HJ, Chen YH, Parker LM, Savoie J, Younger J, Kuter I, Ryan PD, Garber JE, Chen H, Campos SM, Shulman LN, Harris LN, Gelman R, Winer EP. Burstein HJ, et al. Among authors: savoie j. Clin Cancer Res. 2008 Dec 1;14(23):7871-7. doi: 10.1158/1078-0432.CCR-08-0593. Clin Cancer Res. 2008. PMID: 19047116 Clinical Trial.